Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.
Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.
Benjamin Leon Musher, MD, reflects on the progress that has been made in hepatocellular carcinoma and highlights promising combinations that are emerging in the space.
In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer.
Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.
Jordan D. Berlin, MD, sheds light on current and future directions in the field of locally advanced pancreatic cancer.
Derek R. McHaffie, MD, discusses the role of radiation therapy in the treatment of gastrointestinal cancers and the impact of radionuclide therapy in patients with neuroendocrine tumors.
J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.
Kunal C. Kadakia, MD, highlight key takeaways from the the PROMID, CLARINET, and NETTER-1 trials and explains how their findings have been applied to clinical practice.
Jimmy J. Hwang, MD, sheds light on updates in both metastatic pancreatic cancer and advanced hepatocellular carcinoma that have created new complexities for researchers.